Antisense Oligonucleotide for Spinal Muscular Atrophy

Status Recruiting

Clinical Trial Summary

This is a longitudinal, multiple-center, observational study of patients genetically confirmed chromosome 5q SMA to monitor the efficacy, safety, tolerability of SPINRAZA® (nusinersen) for up to 24 months.

Clinical Trial Description

SPINRAZA® (nusinersen) is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Nusinersen, approved by the FDA for treatment of SMA in 2016, was approved by the Chinese National Medical Products Administration in 2019. This is a prospective, longitudinal, multi-center, observational study designed to evaluate the efficacy, safety, tolerability and of nusinersen in patients genetically confirmed chromosome 5q SMA in China. Subjects with SMA I/II/III who are planning to initiate treatment with nusinersen will be enrolled in this study. All patients will be treated by their physicians according to standard clinical practice. SPINRAZA® (nusinersen) is administered as an intrathecal injection. A total of 5ml of cerebrospinal fluid (CSF) will be removed prior to administration of SPINRAZA® (nusinersen), which will be collected by the study. Neurofilament light chain (NfL) in CSF and blood will be assessed for the efficacy of nusinersen, as well as motor and pulmonary function. There will be a total of nine visits. All the patients with 5q SMA receiving nusinersen will be visited face to face at baseline, day 14, day 28 and day 63 after treatment initiation, and then 4-month intervals through month 24/22. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05187260
Study type	Observational
Source	First Affiliated Hospital of Fujian Medical University
Contact	Yi Lin, MD, PhD
Phone	13615039153
Email	linyi7811@163.com
Status	Recruiting
Phase
Start date	January 1, 2022
Completion date	January 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04851873` - Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)	Phase 3
Completed	`NCT03223051` - Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy	N/A
Completed	`NCT04335942` - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor	N/A
Recruiting	`NCT05794139` - Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy	Phase 2
Not yet recruiting	`NCT06300996` - Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb	N/A
Not yet recruiting	`NCT00961103` - Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)	N/A
Completed	`NCT02003937` - Aerobic Training in Patients With Spinal Muscular Atrophy Type III	N/A
Completed	`NCT00227266` - Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Phase 2
Completed	`NCT00374075` - Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy	Phase 1
Enrolling by invitation	`NCT05539456` - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Recruiting	`NCT05779956` - Personalized Medicine for SMA: a Translational Project
Recruiting	`NCT03300869` - Natural History of Types 2 and 3 SMA in Taiwan
Recruiting	`NCT03217578` - Neonatal Spinal Muscular Atrophy (SMA) Screening
Completed	`NCT01703988` - An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy	Phase 1/Phase 2
Withdrawn	`NCT02235090` - Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting	N/A
Completed	`NCT02123186` - Newborn Screening for Spinal Muscular Atrophy	N/A
Completed	`NCT00756821` - A Pilot Study of Biomarkers for Spinal Muscular Atrophy	N/A
Completed	`NCT00004771` - Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease	Phase 2
Recruiting	`NCT05366465` - Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
Recruiting	`NCT06310421` - Spinal Muscular Atrophy Neonatal Screening Program